DUBLIN, May 1, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today that it will host a live webcast and conference call on Friday, May 2, 2014 at 4:30 p.m. ET (or 1:30 p.m. PT) to review interim clinical data from the ongoing Phase 1 study of NEOD001 presented as part of the poster session at the XIV International Symposium on Amyloidosis earlier this week.
The live webcast and conference call can be accessed as follows:
Dial-in: (877) 887-5215 (U.S. toll free) or (315) 625-3069 (international)
Conference ID Number: 41142060
A replay of the webcast will be available until May 10 via dial-in to (855) 859-2056 (U.S. toll free) or (404) 537-3406 (international), Conference ID Number 41142060, or via webcast on the investor relations section of Prothena's website at http://ir.prothena.com.
Prothena Corporation plc is a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion. We focus on therapeutic monoclonal antibodies directed specifically to disease-causing proteins. Our antibody-based product candidates target a number of potential indications including AL and AA forms of amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002) and novel cell adhesion targets involved in inflammatory diseases and cancers (PRX003).